Table 4.

Univariate Analysis of the Presence of SSCP Band “Shift” in Sequential Plasma Samples from 97 Women^*

Variables	Odds Ratio (95% Confidence Interval)	P Value	Trend P Value
Age (years)
<35	Reference group
35–40	1.06 (0.58–1.93)	0.85
>40	0.75 (0.40–1.38)	0.35
Race
White	Reference group
Black	1.38 (0.64–2.98)	0.41
Hispanic	0.95 (0.40–2.26)	0.91
HCV-RNA (IU/mL)
<1,310,000	Reference group
1,310,001–2,740,000	0.66 (0.29–1.54)	0.34
2,740,001–3,940,000	0.67 (0.28–1.63)	0.38	0.10
>3,940,000	0.44 (0.18–1.09)	0.07
HIV-viral load (copies/mL)
<5000	Reference group
5000–9999	0.79 (0.23–2.76)	0.71
10,000–49,000	0.63 (0.29–1.40)	0.26	0.03
50,000–99,999	0.63 (0.25–1.55)	0.31
100,000+	0.30 (0.11–0.84)	0.02
Intravenous drug use (in the past 6 months)
No	Reference group
Yes	2.67 (0.90–7.75)	0.07
Current smoking
No	Reference group
Yes	1.93 (0.83–4.49)	0.13
Antiretroviral therapy
None	Reference group
Monotherapy	0.99 (0.41–2.41)	0.99
Combination therapy	1.47 (0.75–2.89)	0.26
Current HAART use
No	Reference group
Yes	4.28 (2.53–7.22)	<0.0001
CD4 cell count/mm3
>500	Reference group
350–500	0.88 (0.39–1.98)	0.76
200–349	0.37 (0.16–0.86)	0.02	0.08
<200	0.60 (0.25–1.43)	0.25
CD8 cell count/mm3
<500	Reference group
500–1199	0.66 (0.30–1.47)	0.31	0.13
1200 or more	1.48 (0.56–3.94)	0.43
Heroin use
No	Reference group
Yes	2.33 (0.85–6.40)	0.52
Cocaine use
No	Reference group
Yes	1.12 (0.52–2.44)	0.77
Methadone use
No	Reference group
Yes	2.89 (0.44–18.9)	0.27
Number of sex partners
None	Reference group
1	0.71 (0.34–1.47)	0.35	0.30
2 or more	0.64 (0.25–1.60)	0.34

^*All the exposures are from previous visit, except for HAART, which is from the current visit.